Advertisement

Fertility regulation in nursing women: VII. Influence of NORPLANTR

Levonorgestrel implants upon lactation and infant growth
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      The objective of this study was to test the influence of NORPLANTR∗ implants upon lactation and infant growth. The results obtained during the first postpartum year are reported. One-hundred women were enrolled in the implant group. The control group was formed by 100 women who received a Copper T IUD. Treatments were administered at day 55 ± 3. At admission all subjects were in exclusive breastfeeding with an adequate weight increase of the infant. No significant differences were found between the treated and control groups in the percentage of women in full nursing at different postpartum intervals, except for the 12th month postpartum where a lower percentage of cases from the NORPLANTR group was in the full nursing category. No difference was found in the time of weaning. The infants showed a normal weight gain rate in both groups although the girls from the NORPLANTR group showed a significantly lower daily weight increase during the 4th month than the girls from the IUD group. No pregnancies were diagnosed. No women asked for implant removal during the first year. No serious side effects related to treatment were detected. Bleeding irregularities were rare during breastfeeding which is in contrast with what occurs in non-nursing women treated with NORPLANTR implants. Levonorgestrel concentrations found in milk were variable and individual values ranged from 23 to 311 pg/ml. The dose received by the infant can be estimated around 15 to 18 ng/Kg/day during the first month of treatment when the higher plasma values of levonorges trel are observed. These levels in conjunction with the clinical observations reported here minimize the potential problems associated with levonorgestrel transference through maternal milk. Nevertheless, long-term studies are required to settle this matter and until more information is available, NORPLANTR implant use in lactating women should be limited to cases who require a highly effective contraceptive method and where non-hormonal methods of similar effectiveness are contraindicated or unacceptable.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sivin I.
        • Díaz S.
        • Holma P.
        • Alvarez-Sánchez F.
        • Robertson D.N.
        A four-year clinical study of NORPLANTR implants.
        Stud Fam Plann. 1983; 14: 184-191
        • Sivin I.
        • Alvarez-Sánchez F.
        • Díaz S.
        • Holma P.
        • Coutinho E.
        • McDonald O.
        • Robertson D.N.
        • Stern J.
        Three-year experience with NORPLANT subdermal contraception.
        Fertil Steril. 1983; 39: 799-808
        • Sivin I.
        • Brown G.F.
        The introduction of NORPLANTR implants.
        Stud Fam Plann. 1983; 14: 193-193
        • McCann M.F.
        • Liskin L.S.
        • Piotrow P.T.
        • Rinehart W.
        • Fox G.
        La lactancia materna, la fecundidad y la planificación familiar.
        Population Reports Series J. 1982; : 1-3
        • Croxatto H.B.
        • Díaz S.
        • Miranda P.
        • Eiamsson K.
        • Johansson E.D.B.
        Plasma levels of levonorgestrel in women during longterm use of NORPLANT®.
        Contraception. 1981; 23: 197-209
        • Nilsson S.
        • Nygren K-G.
        • Johansson E.D.B.
        D-Norgestrel concentrations in maternal plasma, milk, and child plasma during administration of oral contraceptives to nursing women.
        Am J Obstet Gynecol. 1977; 129: 178-184
        • Díaz S.
        • Peralta O.
        • Juez G.
        • Herreros C.
        • Casado M.E.
        • Salvatierra A.M.
        • Miranda P.
        • Durán E.
        • Croxatto H.B.
        Fertility regulation in nursing women: III. Short-term influence of a low-dose combined oral contraceptive upon lactation and infant growth.
        Contraception. 1983; 27: 1-11
        • Croxatto H.B.
        • Díaz S.
        • Peralta O.
        • Juez G.
        • Herreros C.
        • Casado M.E.
        • Salvatierra A.M.
        • Miranda P.
        • Durán E.
        Fertility regulation in nursing women: IV. Long-term influence of a low-dose combined oral contraceptive initiated at day 30 postpartum upon lactation and infant growth.
        Contraception. 1983; 27: 13-25
        • Peralta O.
        • Díaz S.
        • Juez G.
        • Herreros C.
        • Casado M.E.
        • Salvatierra A.M.
        • Miranda P.
        • Durán E.
        • Croxatto H.B.
        Fertility regulation in nursing women: V. Long-term influence of a low-dose combined oral contraceptive initiated at day 90 postpartum upon lactation and infant growth.
        Contraception. 1983; 27: 27-38
        • Díaz S.
        • Peralta O.
        • Juez G.
        • Salvatierra A.M.
        • Casado M.E.
        • Durán E.
        • Croxatto H.B.
        Fertility regulation in nursing women: I. The probability of conception in full nursing women living in an urban setting.
        Biosoc Sci. 1982; 14: 329-341
        • Robertson D.N.
        • Sivin I.
        • Nash H.A.
        Release rates of levonorgestrel from SilasticR capsules, homogeneous rods and covered rods in humans.
        Contraception. 1983; 27: 483-495
        • Moore D.E.
        • Roy S.
        • Stanczyk F.Z.
        • Mishell D.R.
        Bleeding and serum d-norgestrel, estradiol and progesterone patterns in women using d-norgestrel subdermal polysiloxane capsules for contraception.
        Contraception. 1978; 17: 315
        • Weiner E.
        • Johansson E.D.B.
        Plasma levels of d-norgestrel, estradiol and progesterone during treatment with Silastic implants containing d-norgestrel.
        Contraception. 1976; 14: 81
        • Heikkila M.
        • Haukkamaa M.
        • Luukkainen T.
        Levonorgestrel in milk and plasma of breastfeeding women with a levonorgestrel-releasing IUD.
        Contraception. 1982; 25: 41-49
      1. Texbook of Pediatrics. W.B. Saunders Co, Philadelphia1964: 42
        • World Health Organization
        Contemporaty Patterns of Breast-feeding.
        1981 (Geneva)
        • Waterlow J.C.
        • Thomson A.M.
        Observations on the adequacy of breast-feeding.
        The Lancet. 1979; II: 238